What happened
J2Kbio reported consolidated results for FY2025: revenue of US$22.8M (−0.5% year on year), operating profit of US$2.02M (−19.5% year on year) and net income of US$1.82M (from a loss a year earlier).
Korean rules require this filing when revenue or profit moves 30% or more from the prior year (15% for large companies). The figures are the company's own and may not be audited yet.
| Revenue | US$22.8M |
|---|---|
| Revenue vs a year earlier | −0.5% |
| Operating profit | US$2.02M |
| Net income | US$1.82M |
| Period | FY2025 (consolidated) |
| Filed | 2026-02-12, Change of 30% or more in revenue or profit/loss structure (15% for large companies) |
| Source | DART rcept 20260212900618 → open original filing |
Source: DART. Information only, not investment advice.